Emerging Agents in Renal Cell Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2011-11-29

AUTHORS

Sumanta Kumar Pal , David Y. Josephson , Przemyslaw Twardowski , David I. Quinn

ABSTRACT

The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of six targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the six agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, and bevacizumab), and (2) inhibitors of the mammalian target of rapamycin (mTOR, everolimus, and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm, including novel VEGF-directed therapies such as axitinib and tivozanib. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes, or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies – ranging from vaccine therapy to cytotoxic chemotherapy – that may add to the current armamentarium for mRCC. More... »

PAGES

285-301

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_19

DOI

http://dx.doi.org/10.1007/978-3-642-21858-3_19

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035965315


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Genitourinary Oncology, Kidney Cancer Program, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Genitourinary Oncology, Kidney Cancer Program, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Sumanta Kumar", 
        "id": "sg:person.01162002222.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Genitourinary Oncology, Kidney Cancer Program, Department of Urology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Genitourinary Oncology, Kidney Cancer Program, Department of Urology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Josephson", 
        "givenName": "David Y.", 
        "id": "sg:person.0605012571.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605012571.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Twardowski", 
        "givenName": "Przemyslaw", 
        "id": "sg:person.01176726517.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176726517.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cancer Medicine, Developmental Therapeutics Program, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, 90089, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Division of Cancer Medicine, Developmental Therapeutics Program, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, 90089, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-11-29", 
    "datePublishedReg": "2011-11-29", 
    "description": "The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of six targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the six agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, and bevacizumab), and (2) inhibitors of the mammalian target of rapamycin (mTOR, everolimus, and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm, including novel VEGF-directed therapies such as axitinib and tivozanib. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes, or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies \u2013 ranging from vaccine therapy to cytotoxic chemotherapy \u2013 that may add to the current armamentarium for mRCC.", 
    "editor": [
      {
        "familyName": "Lara,", 
        "givenName": "Primo N.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-21858-3_19", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-21857-6", 
        "978-3-642-21858-3"
      ], 
      "name": "Kidney Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "renal cell carcinoma", 
      "cell carcinoma", 
      "landscape of therapy", 
      "vascular endothelial growth factor", 
      "endothelial growth factor", 
      "antitumor immunity", 
      "vaccine therapy", 
      "cytotoxic chemotherapy", 
      "current armamentarium", 
      "therapy", 
      "mammalian target", 
      "growth factor", 
      "carcinoma", 
      "novel mechanism", 
      "agents", 
      "chemotherapy", 
      "axitinib", 
      "tivozanib", 
      "armamentarium", 
      "disease", 
      "mechanistic categories", 
      "immunity", 
      "rapamycin", 
      "treatment", 
      "inhibitors", 
      "approval", 
      "past decade", 
      "current chapter", 
      "target", 
      "factors", 
      "mechanism", 
      "milestones", 
      "categories", 
      "decades", 
      "chapter", 
      "paradigm", 
      "community", 
      "mind", 
      "range", 
      "research community", 
      "axes", 
      "landscape", 
      "book"
    ], 
    "name": "Emerging Agents in Renal Cell Carcinoma", 
    "pagination": "285-301", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035965315"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-21858-3_19"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-21858-3_19", 
      "https://app.dimensions.ai/details/publication/pub.1035965315"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_257.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-21858-3_19"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_19'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_19'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_19'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-21858-3_19'


 

This table displays all metadata directly associated to this object as RDF triples.

136 TRIPLES      22 PREDICATES      67 URIs      60 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-21858-3_19 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N455ee759580c4870910bef19f1614d86
4 schema:datePublished 2011-11-29
5 schema:datePublishedReg 2011-11-29
6 schema:description The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of six targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the six agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, and bevacizumab), and (2) inhibitors of the mammalian target of rapamycin (mTOR, everolimus, and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm, including novel VEGF-directed therapies such as axitinib and tivozanib. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes, or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies – ranging from vaccine therapy to cytotoxic chemotherapy – that may add to the current armamentarium for mRCC.
7 schema:editor Nd01619fe860f435a9063415abfcc9fab
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N9be6a671d56a4ebd98798c49c57bbe5a
11 schema:keywords agents
12 antitumor immunity
13 approval
14 armamentarium
15 axes
16 axitinib
17 book
18 carcinoma
19 categories
20 cell carcinoma
21 chapter
22 chemotherapy
23 community
24 current armamentarium
25 current chapter
26 cytotoxic chemotherapy
27 decades
28 disease
29 endothelial growth factor
30 factors
31 growth factor
32 immunity
33 inhibitors
34 landscape
35 landscape of therapy
36 mammalian target
37 mechanism
38 mechanistic categories
39 metastatic renal cell carcinoma
40 milestones
41 mind
42 novel mechanism
43 paradigm
44 past decade
45 range
46 rapamycin
47 renal cell carcinoma
48 research community
49 target
50 therapy
51 tivozanib
52 treatment
53 vaccine therapy
54 vascular endothelial growth factor
55 schema:name Emerging Agents in Renal Cell Carcinoma
56 schema:pagination 285-301
57 schema:productId N7a65a19089cf4b8bb5e646801c1b3187
58 N83a7bdac83a9469faebc25e27c31a293
59 schema:publisher N658d7cce496f43f8b62db94e0f51acb8
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035965315
61 https://doi.org/10.1007/978-3-642-21858-3_19
62 schema:sdDatePublished 2022-10-01T06:55
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher Nbc942c7850024e4998dc695ca9a87730
65 schema:url https://doi.org/10.1007/978-3-642-21858-3_19
66 sgo:license sg:explorer/license/
67 sgo:sdDataset chapters
68 rdf:type schema:Chapter
69 N1b0cdb5e86624be19bff00ab413a2d6f schema:familyName Jonasch
70 schema:givenName Eric
71 rdf:type schema:Person
72 N37fed15f7b67458e96ad0350b671d14d rdf:first sg:person.0605012571.62
73 rdf:rest Nc63cdb74f6d0405b89c9ce3308535082
74 N455ee759580c4870910bef19f1614d86 rdf:first sg:person.01162002222.57
75 rdf:rest N37fed15f7b67458e96ad0350b671d14d
76 N64ca5b53e7e74adba5a162f75b88b6e7 schema:familyName Lara,
77 schema:givenName Primo N.
78 rdf:type schema:Person
79 N658d7cce496f43f8b62db94e0f51acb8 schema:name Springer Nature
80 rdf:type schema:Organisation
81 N699b1373fe52478daa61349484625823 rdf:first N1b0cdb5e86624be19bff00ab413a2d6f
82 rdf:rest rdf:nil
83 N7a65a19089cf4b8bb5e646801c1b3187 schema:name doi
84 schema:value 10.1007/978-3-642-21858-3_19
85 rdf:type schema:PropertyValue
86 N83a7bdac83a9469faebc25e27c31a293 schema:name dimensions_id
87 schema:value pub.1035965315
88 rdf:type schema:PropertyValue
89 N9be6a671d56a4ebd98798c49c57bbe5a schema:isbn 978-3-642-21857-6
90 978-3-642-21858-3
91 schema:name Kidney Cancer
92 rdf:type schema:Book
93 Na2e0e0bc42b44625a2a616cc20a71260 rdf:first sg:person.01013134010.15
94 rdf:rest rdf:nil
95 Nbc942c7850024e4998dc695ca9a87730 schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 Nc63cdb74f6d0405b89c9ce3308535082 rdf:first sg:person.01176726517.42
98 rdf:rest Na2e0e0bc42b44625a2a616cc20a71260
99 Nd01619fe860f435a9063415abfcc9fab rdf:first N64ca5b53e7e74adba5a162f75b88b6e7
100 rdf:rest N699b1373fe52478daa61349484625823
101 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
102 schema:name Biological Sciences
103 rdf:type schema:DefinedTerm
104 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
105 schema:name Biochemistry and Cell Biology
106 rdf:type schema:DefinedTerm
107 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
108 schema:familyName Quinn
109 schema:givenName David I.
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
111 rdf:type schema:Person
112 sg:person.01162002222.57 schema:affiliation grid-institutes:grid.410425.6
113 schema:familyName Pal
114 schema:givenName Sumanta Kumar
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57
116 rdf:type schema:Person
117 sg:person.01176726517.42 schema:affiliation grid-institutes:grid.410425.6
118 schema:familyName Twardowski
119 schema:givenName Przemyslaw
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176726517.42
121 rdf:type schema:Person
122 sg:person.0605012571.62 schema:affiliation grid-institutes:grid.410425.6
123 schema:familyName Josephson
124 schema:givenName David Y.
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605012571.62
126 rdf:type schema:Person
127 grid-institutes:grid.410425.6 schema:alternateName Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
128 Division of Genitourinary Oncology, Kidney Cancer Program, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
129 Division of Genitourinary Oncology, Kidney Cancer Program, Department of Urology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
130 schema:name Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
131 Division of Genitourinary Oncology, Kidney Cancer Program, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
132 Division of Genitourinary Oncology, Kidney Cancer Program, Department of Urology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, 91010, Duarte, CA, USA
133 rdf:type schema:Organization
134 grid-institutes:grid.42505.36 schema:alternateName Division of Cancer Medicine, Developmental Therapeutics Program, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, 90089, Los Angeles, CA, USA
135 schema:name Division of Cancer Medicine, Developmental Therapeutics Program, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, 90089, Los Angeles, CA, USA
136 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...